

**FORM 7**  
**MONTHLY PROGRESS REPORT**  
**For the Month of February, 2021**

Name of CSE Issuer: **Pure Extracts Technologies Inc. (the “*Issuer*”, the “*Company*” or “*Pure Extracts*”)**

Trading Symbol: **PULL**

Number of Outstanding Listed Securities: **80,387,037 common shares**

Date of filing: **March 2, 2021**

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Company has been granted its Standard Processing License by Health Canada under the Cannabis Act and is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC and CBD based extracted oils. Additionally, Pure Extracts is presently expanding its business to include functional mushrooms extraction by working on functional mushroom extraction processes compatible with its existing infrastructure. Pure Extracts has a fully built CO<sub>2</sub> extraction facility built to European Union GMP standards and intends to seek EU-GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal.**

- **On February 10, 2021, the Company announced that it recently contracted its first commercial sale of CBD oil and is preparing to deliver the first of what it believes will be multiple shipments this year of its 85% pure CBD distillate under this contract. The Company’s high purity distillate is ideally suited for use in most cannabis 2.0 products including edibles, vape pens and beverages.**
  - **On February 23, 2021, the Company announced announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has submitted an application to Health Canada to amend its license to permit the sale of cannabis extract products to provincially authorized distributors and retailers nationwide.**
2. Provide a general overview and discussion of the activities of management.  
**Please see item 1.**
  3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or

production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Please see item 1.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

- **On February 16, 2021, the Company announced its licensing deal with U.S. based Taste-T, LLC ("Taste-T").**

- **On February 23, 2021, the Company recently announced a distribution agreement with large Canadian Licensed Producer to distribute Pure Extracts' vape and edible products through their established provincial distribution channels.**

- **On February 25, 2021, the Company announced that its wholly owned subsidiary, Pure Extracts Manufacturing Corp.'s distribution partner has submitted a Notice of New Cannabis Product ("NNCP") application to Health Canada on behalf of the company seeking approval for its retail cannabis products including cannabis extracts and edible cannabis.**

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

7. Describe the acquisition of new customers or loss of customers.

**None.**

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None.**

9. Report any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None.**

10. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
- None.**
12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
- None.**
13. Provide details of any securities issued and options or warrants granted.
- **In the month of February, a total of:**
    - **269,000 common shares were issued pursuant to exercise of performance rights.**
    - **542,500 common shares were issued pursuant to the exercise of warrants.**
    - **25,000 common shares were issued pursuant to the exercise of stock options.**
14. Provide details of any loans to or by Related Persons.
- None.**
15. Provide details of any changes in directors, officers or committee members.
- None.**
16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
- None.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: March 2, 2021

Yana Popova  
Name of Director or Senior  
Officer

"Yana Popova"  
Signature

Chief Financial Officer  
Official Capacity

<b>Issuer Details</b>		
Name of Issuer <b>Pure Extracts Technologies Corp.</b>	For Month End <b>February, 2021</b>	Date of Report YY/MM/DD <b>2021/03/02</b>
Issuer Address <b>7341 Industrial Way</b>		
City/Province/Postal Code <b>Pemberton, BC, V0N 2K0</b>	Issuer Fax No. ( )	Issuer Telephone No. <b>1 (604) 328-5598</b>
Contact Name: <b>Yana Popova</b>	Contact Position: <b>CFO &amp; Director</b>	Contact Telephone No. <b>1 (604) 328-5598</b>